Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis

References

• van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease out-come in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56:433–40.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;313:15–24.
   Google Scholar
• Harrison BJ, Symmons DP, Barrett EM, Silman AJ. The per-formance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol. 1998;25:2324–30.
   PubMed Web of Science ®Google Scholar
• Huizinga TWJ, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum. 2002;46:1155–9.
   Google Scholar
• Verpoort KN, van Dongen H, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Undifferentiated arthritis-disease course assessed in several inception cohorts. Clin Exp Rheumatol. 2004;22:S12–7.
   Web of Science ®Google Scholar
• Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Auto-antibodies to cyclic citrullinated peptides (CCP) predicts pro-gression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709–15.
   PubMed Web of Science ®Google Scholar
• Vittecoq O, Incaurgarat B, Jouen-Beades F, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrul-linated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol. 2004;135 :173–80.
   Google Scholar
• Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)]. Ann Rheum Dis. 2007;66:34–5.
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845–51.
   Google Scholar
• Emad Y, Ragab Y, Shaarawy A, Abou-Zeid A, Saad A, Fawzy M, et al. Can magnetic resonance imaging differentiate undif-ferentiated arthritis based on knee imaging? J Rheumatol. 2009;36:1963–70.
   Google Scholar
• van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58:2241–7.
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwin-derman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446–51.
   Google Scholar
• van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with antirheumatic drugs. A randomized, con-trolled trial. Ann Intern Med. 1996;124:699–707.
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Rau R. Radiographic healing with sustained clinical remission in a patient with rheumatoid arthritis receiving methotrexate monotherapy. Arthritis Rheum. 2002;46:2804–7.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 2003;48:3039–45.
   Google Scholar
• van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prog-nostic value of the antiperinuclear factor, anti-citrullinated pep-tide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:689–97.
   Google Scholar
• Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62:120–6.
   PubMed Web of Science ®Google Scholar
• VencovskY J, Machkek S, Sedová L, Kafková J, Gatterová J, Pesdková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:427–30.
   PubMed Web of Science ®Google Scholar
• Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chalès G, Le Henaff C, et al. Value of antibodies to citrulfine-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol. 2003;30:2535–9.
   Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64:196–201.
   PubMed Web of Science ®Google Scholar
• Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheu-matoid arthritis. Arthritis Rheum. 2000;43:1831–5.
   Google Scholar
• Visser H, Le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early? A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357–65.
   PubMed Web of Science ®Google Scholar
• Pruijn GJM, Vossenaar 1 ER, Drijfhout JW, van Venrooij1 WJ, Zendman MW. Anti-CCP antibody detection facilitates early diagnosis and prognosis of rheumatoid arthritis. Curr Rheumatol Rev. 2005;1:1–7.
   Google Scholar
• Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–3.
   Google Scholar
• Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–9.
   Google Scholar
• Vander Cruyssen B, Hoffman IE, Peene I, Union A, Mielants H, Meheus L, et al. Prediction models for rheumatoid arthritis dur-ing diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann Rheum Dis. 2007;66:364–9.
   PubMedGoogle Scholar
• Van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC, Huizinga TW. Long-term outcome of rheumatoid arthritis that presented with undifferentiated arthritis compared to rheu-matoid arthritis at presentation: an observational cohort study. Ann Rheum Dis. 2006;65:20–5.
   PubMed Web of Science ®Google Scholar